NCT07102004

Study of MHB088C for Patients With Advanced Solid Malignant Tumors

A Phase I/II Study of MHB088C for Patients With Advanced Malignant Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 515 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety/tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of MHB088C in participants with advanced solid tumors

Conditions

• Advanced/Metastatic Solid Tumors

Interventions

Type	Name	Description
DRUG	MHB088C for Injection	MHB088C for Injection, an antibody drug-conjugated molecule (ADC) MHB088C will be administered intravenously at a frequency of once every 2 weeks (Q2W) or every 3 week (Q3W).

Timeline

• Start date: 2023-06-20
• Primary completion: 2026-07-01
• Completion: 2027-07-01
• First posted: 2025-08-03
• Last updated: 2025-08-03

Locations

1 site across 1 country: China